Treatment for pulmonary manifestations of juvenile systemic sclerosis
نویسندگان
چکیده
Purpose Children with systemic sclerosis (SSc) may develop severe alveolitis with progressive, potentially fatal interstitial fibrosis. There have been no controlled trials for treatment of juvenile SSc. Adult trials suggest benefit from cyclophosphamide (CY) therapy, though with significant risk for adverse events. As part of a larger study to develop objective clinical and radiological measures for outcomes in juvenile SSc, we reviewed the courses of seven patients with SSc lung disease who were treated with extensive courses of CY or methotrexate.
منابع مشابه
Anticardiolipin Antibodies in Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background: Antiphospholipid antibody syndrome (APS) can either occur as a primary syndrome or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in blood, measured by a standardized ELISA is the most acceptable laboratory criteria. APS IgG isotype, particularly IgG2 subclass is more strongly associated ...
متن کاملThe Pulmonary Manifestations of Generalised Scleroderma
Two aspects of generalised scleroderma have received much attention in recent years. Firstly, the widespread and sclerotic nature of the disease process has been embodied in the term “progressive systemic sclerosis,” proposed by Goetz’ in 1945, and since adopted by other authors. Secondly, connective tissue alterations are now regarded as an integral part of this entity which answers all the cr...
متن کاملTomography patterns of lung disease in systemic sclerosis*
Currently, lung impairment is the leading factor responsible for the morbidity and mortality associated with systemic sclerosis. Therefore, the recognition of the various tomography patterns becomes decisive in the clinical management of these patients. In high-resolution computed tomography studies, the most common pattern is that of nonspecific interstitial pneumonia. However, there are other...
متن کاملIs mTOR inhibition a systemic treatment for tuberous sclerosis?
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder characterized by the development of hamartomas in several organs. Mutations in the TSC1 and TSC2 tumor suppressor genes determin overactivation of the mammalian target of rapamycin (mTOR) signaling pathway and subsequent abnormalities in numerous cell processes. As a result, mTOR inhibitors such as sirolimus and everolimus have ...
متن کامل[Therapy of systemic sclerosis].
The treatment of the patient with systemic sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud's phenomenon. Some of these drugs namely cyclophosphamide and iloprost await to be confirmed as disease modifying...
متن کامل